OR WAIT null SECS
The collaboration will focus on developing manufacturing solutions for biosimilars.
On Sept. 12, 2018, Pall, a provider of filtration, separation, and purification solutions, has announced a strategic partnership between its Pall Biotech business unit and Aetos Biologics, a San Francisco, CA-based biosimilar cell-line development company. The companies will collaborate on biosimilar manufacturing solutions.
Under the agreement, Pall Biotech will provide access to next-generation bioprocess equipment, such as the Allegro STR single-use stirred tank bioreactor for good manufacturing practices (GMP) manufacturing, and consumables to enable efficient biosimilar production. Aetos Biologics will provide high-quality/high-titer cell lines and scalable manufacturing processes.
“Biosimilars are a replication of a successful biopharmaceutical product. While they are much less expensive than innovator molecules, the complexities in their development make it critical to work with the right equipment and service providers,” said Mario Philips, VP & General Manager at Pall Biotech. “We are excited to partner with the Aetos Biologics team to advance the market impact of biosimilars and deliver lower priced, high-quality options to end users.”
“Our team is constantly working to optimize a growing pipeline of high-yield biosimilars with outstanding quality,” said Amita Goel, founder and CEO of Aetos Biologics, in a company press release. “Through this strategic partnership with Pall Biotech, we can ensure that the exceptional quality we achieve in scaled-up processes is efficiently transferred and reproduced by the client.”
By aligning Pall Biotech equipment, including bioreactors, mixing and storage, and downstream technologies with Aetos Biologics’ cell lines and manufacturing processes, customers benefit from access to integrated solutions for expedited biosimilars development.